China Universal Asset Management Company’s Pliant Therapeutics PLRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-10,760
Closed -$15.9K – 522
2025
Q3
$15.9K Sell
10,760
-1,569
-13% -$2.39K ﹤0.01% 465
2025
Q2
$14.3K Buy
12,329
+123
+1% +$174 ﹤0.01% 457
2025
Q1
$16.5K Sell
12,206
-697
-5% -$4.23K ﹤0.01% 461
2024
Q4
$170K Buy
12,903
+1,209
+10% +$16.5K 0.02% 338
2024
Q3
$131K Buy
11,694
+4,607
+65% +$57.6K 0.01% 334
2024
Q2
$76.2K Sell
7,087
-4,494
-39% -$57.9K 0.01% 320
2024
Q1
$173K Buy
11,581
+4,652
+67% +$76.7K 0.02% 310
2023
Q4
$125K Buy
6,929
+5,400
+353% +$82.1K 0.02% 253
2023
Q3
$26.5K Buy
1,529
+754
+97% +$13.1K 0.01% 279
2023
Q2
$14K Buy
775
+2
+0.3% +$47 ﹤0.01% 298
2023
Q1
$20.6K Buy
773
+278
+56% +$7.92K 0.01% 217
2022
Q4
$9.57K Buy
495
+39
+9% +$815 ﹤0.01% 231
2022
Q3
$10K Buy
+456
New +$8.72K ﹤0.01% 207

Other funds holding PLRX

China Universal Asset Management Company's PLRX Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 10,760 shares — an estimated $15.9K sold.

China Universal Asset Management Company first reported a position in PLRX in Q3 2022 and held it in 13 quarters. The position peaked at $173K in Q1 2024. 97 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • China Universal Asset Management Company reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 10,760 Pliant Therapeutics shares in Q4 2025, an estimated $15.9K.
  • China Universal Asset Management Company first reported a position in Pliant Therapeutics in Q3 2022 and held it in 13 quarters.
  • China Universal Asset Management Company's Pliant Therapeutics position peaked at $173K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.